about
HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activityTriple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticlesRectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized miceEfficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1Nanotechnology and HIV: potential applications for treatment and prevention.Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection.The Safety of Multiple Flexible Sigmoidoscopies with Mucosal Biopsies in Healthy Clinical Trial Participants.Increasing the effectiveness of vaginal microbicides: a biophysical framework to rethink behavioral acceptabilityState of the science of adherence in pre-exposure prophylaxis and microbicide trials.Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.Safety and anti-HIV assessments of natural vaginal cleansing products in an established topical microbicides in vitro testing algorithm.Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics.Potential impact of vaginal microbicides on HIV risk among women with primary heterosexual partners.Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)Rectal microbicides: can we make them and will people use them?Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histoculturesUser-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidatesLiposomes for HIV prophylaxis.The Microbiological Context of HIV Resistance: Vaginal Microbiota and Mucosal Inflammation at the Viral Point of EntryUsing modeling to help understand vaginal microbicide functionality and create better products.HIV in young men who have sex with men: a review of epidemiology, risk and protective factors, and interventions.Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection.Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicidesSuccesses and challenges of HIV prevention in men who have sex with menMucosal HIV-1 transmission and prevention strategies in BLT humanized miceDurable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimerasRecruitment of HIV-1 target cells at topical mucosal sites: a sensitive and early marker for determining the safety of microbicide candidates.Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSVDesigning preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation propertiesSame-sex sexual behavior of men in Kenya: Implications for HIV prevention, programs, and policy.Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors.Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?An overview of antiretroviral pre-exposure prophylaxis of HIV infection.Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.Anal Douche Practices and Willingness to Use a Rectal Microbicide Enema for HIV Prevention and Associated Factors Among an Internet Sample of HIV-Negative and HIV-Discordant Male Couples in the US.
P2860
Q21076115-CC31E897-AD24-4709-86C3-0728E854C97FQ28393885-FC67F291-0724-4B11-B6D4-F4DB21301E42Q28488527-89EE3E90-94EE-435C-9056-79D60149AE2CQ28729936-D67A1E53-F544-4006-A19A-470839420CCAQ30393980-16B8EF41-5DF1-42AD-829C-D9B5ED13F4E6Q30499941-DB659AEA-0084-4444-A0F4-37DE222EBDB5Q33470044-092C2E51-AC46-4D63-BC50-E1FCE7F7C821Q33761194-F167A358-A731-4153-85D6-35279126D6B4Q33798685-A9C8D312-410D-4DF3-974A-E48A9F00001EQ34030735-F1680CA2-8CD6-4DE6-8D50-8BCE1495171DQ34035880-B7CFC40B-A78E-400A-B66A-025EBA1D5257Q34509294-568CF00B-A25C-4815-9C2F-235AD49C36BEQ34632662-9DEA0C39-FC6B-4586-ABFA-A736481230A9Q34834065-1FAC53A1-7906-430E-9F99-B923A6D91E46Q35012567-D66F196E-0266-481C-9C24-CD2745E3A3E8Q35012572-3F3ED85D-76EE-4329-BD05-4D0E2D22B48FQ35014689-A258D222-7A5E-4989-A4F3-DF16BB188BFBQ35082722-EAE0A158-898F-4A56-BCDC-4AF6B755F910Q35140303-2D9D82B7-9C68-4521-9143-A5D2FAD4C231Q35686901-06C5A3B3-7BF8-468B-81AF-E126FACB7C31Q35852782-FE0D9448-2433-4533-9D9E-38EA587959AEQ35913838-DBAE0CA1-B0F6-4B3D-AFF3-30938F57F501Q35955668-693A03C5-0ADB-4ECA-A259-5C191B094FA4Q36171536-EEDE7AB3-CEC2-401A-82F9-1B3E68E9B6A5Q36358774-71670A27-9358-4494-830B-E6D2504BC6FCQ36359133-4BFE795D-F484-445B-A11A-7D143B0B32D3Q36785795-041D7D95-A946-4EB7-B97F-5C0A21121487Q36897630-66569DA4-9594-4868-9CA4-BAF5C5C6006AQ36923075-ECA25560-B38A-4F88-8B2A-759631E433DAQ36984469-DB2CA51B-FDB4-4B6E-BE98-506C0E40EABEQ37289548-793447FE-C43D-4C08-B647-532C408D88A9Q37553822-517EEF4B-9E0E-4FC3-BB83-30FDB5115AC7Q37597118-DB221A74-D826-4180-AC6D-E7AD04F14DEFQ37704098-5FB4E278-CDCC-4E31-9383-DD39670A524AQ37707803-FAA6E3B4-E0B4-4A83-A0E0-569088B3D36DQ37855900-2E780101-02A9-4DD2-B79D-D47C5E1A1B02Q38009758-BE20736B-7F21-4DF3-BFC7-E35A9AC2D1DFQ38196410-2A72034E-D2BC-4AA6-8FBB-FC8AF9C0E6A2Q40062702-71874210-BC8C-42D6-A8E0-AB53DAD84663Q40285634-545B9853-88E0-451E-8706-C069328DAF54
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Microbicides for HIV prevention: reality or hope?
@en
Microbicides for HIV prevention: reality or hope?
@nl
type
label
Microbicides for HIV prevention: reality or hope?
@en
Microbicides for HIV prevention: reality or hope?
@nl
prefLabel
Microbicides for HIV prevention: reality or hope?
@en
Microbicides for HIV prevention: reality or hope?
@nl
P1476
Microbicides for HIV prevention: reality or hope?
@en
P2093
Ian McGowan
P356
10.1097/QCO.0B013E328334FE70
P577
2010-02-01T00:00:00Z